Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain
- 1 August 2015
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pain
- Vol. 156 (8), 1382-1395
- https://doi.org/10.1097/j.pain.0000000000000088
Abstract
Enriched-enrolment randomised-withdrawal (EERW) pain trials select, before randomisation, patients who respond by demonstrating a predetermined degree of pain relief and acceptance of adverse events. There is uncertainty over the value of this design. We report a systematic review of EERW trials in chronic non-cancer pain together with a critical appraisal of methods and potential biases in the methods used and recommendations for the design and reporting of future EERW trials. Electronic and other searches found 25 EERW trials published between 1995 and June 2014, involving 5669 patients in a randomised withdrawal phase comparing drug to placebo; 13 (median 107 patients) had a randomised withdrawal phase of six weeks or less, and 12 (median 334) lasted 12-26 weeks. Risks of bias included short duration, inadequate outcome definition, incomplete outcome data reporting, small size, and inadequate dose tapering on randomisation to placebo. Active treatment was usually better than placebo (22/25 trials).This review reduces the uncertainty around the value of EERW trials in pain. If properly designed, conducted, and reported, they are feasible and useful for making decisions about pain therapies. Shorter, small studies can be explanatory; longer, larger studies can inform practice. Current evidence is inadequate for valid comparisons in outcome between EERW and classical trials, though no gross differences were found. This systematic review provides a framework for assessing potential biases and the value of the EERW trials, and for the design of future studies by making recommendations for the conduct and reporting of EERW trials.Keywords
This publication has 80 references indexed in Scilit:
- Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back painJournal of Pain Research, 2013
- Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journalsTrials, 2012
- Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid-Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched, Randomized, Double-Blind, Placebo-Controlled StudyJournal of Pain and Symptom Management, 2011
- Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific LiteraturePLoS Medicine, 2011
- Interpreting patient-reported outcome results: US FDA guidance and emerging methodsExpert Review of Pharmacoeconomics & Outcomes Research, 2011
- Pregabalin in fibromyalgia - responder analysis from individual patient dataBMC Musculoskeletal Disorders, 2010
- Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practiceAnnals Of The Rheumatic Diseases, 2009
- Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic reviewBritish Journal of Clinical Pharmacology, 2008
- The Meaning of Translational Research and Why It MattersJama-Journal Of The American Medical Association, 2008
- Incidence of Epidural Hematoma, Infection, and Neurologic Injury in Obstetric Patients with Epidural Analgesia/AnesthesiaAnesthesiology, 2006